Cooper Companies Q3 2026 Earnings Call Summary
During CooperCompanies' third-quarter earnings call for fiscal year 2026, the company reported results that exceeded expectations and highlighted record free cash flow. The fertility segment at CooperSurgical showed strong growth, while a significant tax matter was resolved favorably. However, CooperVision's performance was impacted by proactive reductions in U.S. channel inventory, which will continue to affect Q4 but reflect healthier demand fundamentals with mid-single-digit consumption growth. The company concluded its strategic review of CooperSurgical and decided against selling the business despite receiving significant interest from potential buyers. The Board unanimously agreed that continued ownership is more beneficial for shareholders at this time. Management also outlined additional steps aimed at strengthening revenue performance, particularly in the CooperVision segment as it moves into fiscal 2027.
Tickers: $COO